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bjectives The purpose of this study was to examine the differences in in-hospital and longer-term
ortality for ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease as
function of whether they underwent single-vessel (culprit vessel) percutaneous coronary interven-
ions (PCIs) or multivessel PCI.
ackground The optimal treatment of patients with STEMI and multivessel disease is of continuing
nterest in the era of drug-eluting stents.
ethods STEMI patients with multivessel disease undergoing PCIs in New York between January 1,
003, and June 30, 2006, were subdivided into those who underwent culprit vessel PCI and those
ho underwent multivessel PCI during the index procedure, during the index admission, or staged
ithin 60 days of the index admission. Patients were propensity-matched and mortality rates were
alculated at 12, 24, and 42 months.
esults A total of 3,521 patients (87.5%) underwent culprit vessel PCI during the index procedure.
total of 259 of them underwent staged PCI during the index admission and 538 patients under-
ent staged PCI within 60 days of the index procedure. For patients without hemodynamic compro-
ise, culprit vessel PCI during the index procedure was associated with lower in-hospital mortality
han multivessel PCI during the index procedure (0.9% vs. 2.4%, p  0.04). Patients undergoing
taged multivessel PCI within 60 days after the index procedure had a signiﬁcantly lower 12-month
ortality rate than patients undergoing culprit vessel PCI only (1.3% vs. 3.3%, p  0.04).
onclusions Our ﬁndings support the American College of Cardiology/American Heart Association
ACC/AHA) recommendation that culprit vessel PCI be used for STEMI patients with multivessel disease
t the time of the index PCI when patients are not hemodynamically compromised. However, staged PCI
ithin 60 days after the index procedure, including during the index admission, is associated with risk-
djusted mortality rates that are comparable with the rate for culprit vessel PCI alone. (J Am Coll Car-
iol Intv 2010;3:22–31) © 2010 by the American College of Cardiology Foundation
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23he current American College of Cardiology/American
eart Association (ACC/AHA) guidelines for the manage-
ent of patients with ST-segment elevation myocardial
nfarction (STEMI) recommend primary percutaneous cor-
nary intervention (PCI) as the treatment of choice (1,2).
or most patients with multivessel disease who undergo
rimary PCI for STEMI, it is recommended that only the
ulprit vessel be treated and that other diseased vessels be
ddressed in an elective procedure at another time. Acute
ultivessel PCI is recommended during the index proce-
ure only for patients with hemodynamic compromise (3).
See page 32
The purpose of this study was to examine differences in
n-hospital and longer-term mortality for STEMI patients
ith multivessel disease as a function of whether they under-
ent single-vessel (culprit vessel) PCI or multivessel PCI.
ecause multivessel PCI can be performed at the same time as
ulprit vessel PCI or at a later time, we compared 2 strategies
or multivessel PCI with culprit vessel PCI-multivessel during
he same catheterization laboratory visit as the culprit vessel
CI and multivessel PCI where the nonculprit vessel is not
ttempted in the same visit but is attempted within 60 days of the
ndex procedure. Also, for patients undergoing a staged multives-
el PCI within 60 days, we compared the subset undergoing
taged PCI during the index admission with patients undergoing
ulprit vessel PCI.
ethods
atabases. Data were obtained from New York State’s
ercutaneous Coronary Interventions Reporting System
PCIRS), a mandatory registry in New York that was
nitially developed in 1991. The PCIRS contains detailed
nformation for each patient undergoing PCI in the state
egarding demographic data; pre-procedural risk factors;
eriprocedural complications; types of devices used; extent
f disease and lesions treated; dates of admission, discharge,
nd procedure; discharge disposition and destination; and
ospital and operator identifiers. These data were recorded
t the time of the procedure and discharge by catheteriza-
ion laboratory personnel. Definitions of some variables are
ontained in the Online Appendix; all definitions can be
btained from the New York State Department of Health.
hese data were matched to New York administrative data
nd were audited by the New York State Department of
ealth’s utilization review agent to ensure completeness and
ccuracy.
For this study, the PCIRS data were matched to New
ork’s vital statistics data with patient identifiers so that
atients who are New York residents could be followed after
ischarge for evidence of subsequent death. matients and end points. All multivessel disease patients
ho are New York State residents who experienced an
TEMI within 24 h before undergoing PCI between
anuary 1, 2003, and June 30, 2006, were included in the
tudy, except those with missing ejection fraction (n 703),
eft main disease (n  216), previous open heart surgery
n  503), shock (n  126), or thrombolytic therapy before
CI (n 1,059). The number of patients in the study group
as 4,024. The short-term end point in the study was
n-hospital mortality, and the longer-term end points were
ortality at 12, 24, and 42 months.
tatistical analysis. Differences between patients undergoing
ulprit vessel primary PCI and multivessel PCI at the time of
rimary PCI in the prevalence of various patient risk factors
demographic data, comorbidities, left ventricular function,
emodynamic state, vessels diseased, time since onset of
ymptoms) as well as differences in in-hospital mortality were
ested with chi-square tests and Fisher exact tests.
Because patients were not randomized to the 2 types of
ntervention (culprit-only vs.
ultivessel PCI), we identified
atients’ pre-procedural charac-
eristics that were potentially re-
ated to whether patients under-
ent single-vessel or multivessel
CI and matched patients on
he basis of those characteristics
ith propensity-matched sam-
les (4).
The matching characteristics
ncluded demographic data, left
entricular function, hemody-
amic status, the number and lo-
ation (left anterior descending
oronary artery/no left anterior
escending coronary artery) of diseased coronary vessels, con-
estive heart failure, Thrombolysis In Myocardial Infarction
TIMI) flow, several comorbidities, and device used.
For each of 3 sets of analyses (culprit vessel PCI vs.
ultivessel PCI during the index procedure, culprit vessel PCI
s. staged multivessel PCI during the index admission, culprit
essel PCI vs. staged multivessel PCI within 60 days), these
haracteristics were used to develop a logistic regression model
hat predicted the probability that a given STEMI patient
ould undergo culprit vessel PCI. This value, the propensity
core, was used to match patients without replacement on a
-to-1 basis. For the first set of analyses, a patient undergoing
ultivessel PCI was randomly selected and then matched to a
atient undergoing culprit vessel PCI to minimize the overall
istance in propensity scores between the groups (5–7). Dif-
erences between the 2 matched samples in the prevalence of
ropensity model variables were tested with standardized
ifferences in the observed prevalence of the variables in the
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
PCI  percutaneous
coronary intervention
PCIRS  Percutaneous
Coronary Interventions
Reporting System
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionatched groups (7,8). The propensity matched pairs were then
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24sed to analyze differences in mortality outcomes between the
groups.
The second set of analyses compared the subset of 259
atients undergoing staged PCI who underwent the second
CI during the index admission but not the index procedure
ith a group of propensity-matched culprit vessel-only PCI
atients. In this case, 12-, 24-, and 42-month mortality
ere compared for the propensity-matched groups.
In the third set of analyses, the first group of patients was
efined to be patients who did not undergo multivessel PCI
uring the index PCI but did undergo multivessel PCI within
0 days of discharge. These (n 538) patients consisted of the
59 patients noted in the preceding text who underwent staged
ultivessel PCI during the index admission but not the index
rocedure and an additional 279 patients who underwent
nonemergency) staged multivessel PCI after the index admis-
ion but within 60 days of the index procedure. These patients
ere propensity-matched to 538 patients who underwent
ulprit vessel PCI in the index admission and who were alive
0 days after discharge. The propensity matching process was
dentical to that described in the preceding text for the other 2
ropensity-matched groups. The 12-, 24-, and 42-month
ortality were compared for the propensity-matched groups.
For in-hospital mortality, McNemar’s Test was used to test
or differences in the propensity-matched samples. For the 3
onger-term outcomes, methods were used to compare mor-
ality that take into account that the samples were matched (9).
All tests were 2-sided and conducted at the 0.05 level, and
ll analyses were conducted in SAS version 9.1 (SAS, Cary,
orth Carolina).
esults
f the 4,024 patients in the study, 3,521 (87.5%) underwent
nly culprit vessel revascularization at the time of primary PCI,
nd the remainder underwent multivessel revascularization at
he time of primary PCI. The patients who underwent mul-
ivessel revascularization at the time of primary PCI were
ounger, more likely to have low or higher ejection fractions,
ess likely to have a chronic total occlusion, less likely to have
IMI flow grade2 in the culprit vessel before PCI, and more
ikely to have had bare-metal stents (Table 1).
Tables 2 to 4 present patient characteristic prevalences
fter each of the respective 3 types of multivessel PCI
atients were matched on a 1-to-1 basis with a culprit vessel
CI patient. As indicated in the tables, the C statistics for
he 3 models ranged from 0.62 to 0.69, and no standardized
ifferences in prevalences of patient characteristics in the 3
odels exceeded 10%.
Table 5 presents mortality rates for in-hospital, 12-, 24-,
nd 42-month mortality for the propensity-matched patients
ith culprit vessel PCI and multivessel PCI during the index
rocedure. Although the mortality rates for culprit vessel
atients were lower for each of the time points represented, lone of the mortality differences reached statistical signifi-
ance. At discharge from the hospital, the rates were 2.0% and
.4% (p  0.48), and at 42 months, the rates were 10.8% and
1.8% (p  0.72).
For patients with 2-vessel disease (374 pairs), the rates were
.7% versus 3.8% (p  0.41) at discharge and 9.2% versus
1.7% (p  0.28) at 42 months, whereas for patients with
-vessel disease (129 pairs), the rates were 1.6% versus 2.4%
p 0.61) at discharge and 10.0% versus 12.2% (p  0.83) at
2 months. For patients with complete revascularization (370
airs, all major epicardial vessels with 70% stenosis revascu-
arized), the rates were 2.2% versus 3.6% (p  0.23) at
ischarge and 9.2% versus 12.3% (p  0.16) at 42 months.
oronary artery bypass graft surgery rates after PCI in the
ndex admission were 3.10% versus 0.80% (p  0.003).
When the analyses were restricted to patients without
emodynamic compromise (defined as best we could, given
vailable data elements, as patients without hemodynamic
nstability or ejection fraction 20% or severe ventricular
rrhythmia), mortality rates again favored patients treated with
ulprit vessel revascularization. At discharge from the hospital,
he rates were significantly different in favor of culprit vessel
CI (0.9% and 2.4%, p  0.04). At 24 and 46 months the
ortality differences trended toward significance.
Table 6 presents differences between the subset of staged
ultivessel PCI patients who underwent multivessel PCI in
he index admission and patients who underwent only culprit
essel PCI. The staged group experienced lower mortality rates
t all the time intervals examined, but none of the differences
as significant. At 42 months, the mortality rates were 6.3%
nd 8.4%, respectively (p  0.72).
The 12-, 24-, and 42-month mortality rates for multives-
el disease STEMI patients staged to undergo PCI for
onculprit vessel PCI within 60 days of the index procedure
nd patients undergoing only culprit vessel PCI are pre-
ented in Table 7. These rates are lower than the ones
resented in Table 5, because they represent culprit vessel
CI patients who survived for at least 60 days and multives-
el PCI patients who underwent PCI after discharge. As
oted, the multivessel PCI patients had lower mortality
ates at all time intervals, and the rate was significantly lower
t 12 months (1.3% vs. 3.3%, p  0.04).
iscussion
urrent guidelines recommend that elective PCI should not
e performed in a noninfarct-related artery at the time of
rimary PCI of the infarct-related artery in patients without
emodynamic compromise (3). It is an open question
hether this remains a good idea in the era of drug-eluting
tents, which have been demonstrated by randomized con-
rolled trials and observational studies to be associated with
ower subsequent revascularization rates and by several
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25bservational studies to be associated with lower mortality
or primary PCI and PCI for STEMI patients (10–13).
Several earlier studies have examined the impact of
ultivessel PCI on primary PCI patients with a variety of
Table 1. Risk Factor Prevalence Before Propensity Matching According to
Multivessel CAD
Risk Factor
% in Study Population
(n  4,024)
% With Cu
a
Demographic factors
Age, yrs
59 or less 46.94
60–69 24.18
70–79 18.84
80 or more 10.04
Female 26.09
Race
White 84.37
Black 7.88
Other 7.75
Cardiac factors
No. of vessels diseased
2 no proximal LAD 53.16
2 with proximal LAD 21.89
3 no proximal LAD 16.05
3 with proximal LAD 8.90
Ejection fraction
19% or less 1.94
20%–29% 8.28
30%–39% 18.24
40%–49% 31.56
50% or more 39.99
Hemodynamic instability
Unstable 4.40
CHF history
This admission 7.08
Chronic total occlusion 17.77
TIMI ﬂow grade 2 in culprit vessel 50.89
Comorbidities
Cerebrovascular 4.60
Peripheral vascular 4.13
Diabetes 21.69
Ventricular arrhythmia 1.47
COPD 4.75
Renal dialysis 0.72
Creatinine 2.5 mg 1.02
Type of PCI
Only drug-eluting stent used 60.59
Bare-metal stent used 34.74
No stent used 4.67
New York State, January 1, 2003, to June 30, 2006.
CAD coronary artery disease; CHF congestive heart failure; COPD chronic obstructive pulm
PPCI primary percutaneous coronary intervention; STEMI ST-segment elevation myocardial infnclusion criteria, time frames for nonculprit vessel PCI, outcomes used, and conclusions. Patients studied have
ncluded acute coronary syndromes (14), primary, facili-
ated, and rescue PCI patients (15,16); primary PCI
atients (17–21); and STEMI patients (22). Mortality
Procedure Revascularization Strategy in STEMI Patients With
ssel Revascularization
Time of PPCI
 3,521)
% With Multivessel Revascularization
at the Time of PPCI
(n  503) p Value
0.001
45.84 54.67
24.54 21.67
19.51 14.12
10.11 9.54
26.24 25.05 0.57
0.31
84.13 86.08
8.12 6.17
7.75 7.75
0.46
53.56 50.30
21.58 24.06
15.90 17.10
8.95 8.55
0.01
1.73 3.38
8.38 7.55
18.52 16.30
32.04 28.23
39.34 44.53
4.35 4.77 0.66
6.96 7.95 0.41
19.54 5.37 0.0001
51.95 43.54 0.0004
4.71 3.78 0.35
4.12 4.17 0.95
21.41 23.66 0.25
1.42 1.79 0.52
4.66 5.37 0.48
0.71 0.80 0.83
1.05 0.80 0.59
0.0001
61.09 57.06
33.80 41.35
5.11 1.59
isease; LAD left anterior descending coronary artery; PCI percutaneous coronary intervention;
; TIMI Thrombolysis In Myocardial Infarction.Index
lprit Ve
t the
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onary dutcomes have included in-hospital mortality (14,15),
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26n-hospital/30-day mortality (18), and a combination of
hort-term and longer-term mortality (16,17,19 –22).
he definition of timing of multivessel PCI has also
aried and has included: during the index procedure
14,16,19,21), during the index procedure or hospital stay
17,18), staged PCI during the index hospital stay (20),
uring the index hospital stay or within 7 days of
yocardial infarction (22), and within 24 h of myocardial
nfarction (15).
Conclusions have ranged from significantly lower adverse
utcome rates for culprit vessel PCI (17), trending in favor
Table 2. Risk Factor Prevalence After Propensity Match According to Reva
Multivessel CAD: Culprit Vessel Only Versus Multivessel at the Time of PP
Risk Factor
% in Study Population
(n  1,006)
% With Culprit Vess
at the Tim
(n 
Demographic factors
Age, yrs
59 or less 55.07 55
60–69 21.17 20
70–79 14.91 15
80 or more 8.85 8
Female 23.16 21
Cardiac factors
No. of vessels diseased
2 no proximal LAD 49.80 49
2 with proximal LAD 24.16 24
3 no proximal LAD 16.40 15
3 with proximal LAD 9.64 10
Ejection fraction
19% or less 2.88 2
20%–29% 6.86 6
30%–39% 16.30 16
40%–49% 28.43 28
50% or more 45.53 46
Hemodynamic status
Unstable 3.88 2
CHF history
This admission 7.06 6
Chronic total occlusion 5.47 5
TIMI ﬂow grade 2 41.85 40
Comorbidities
Cerebrovascular 3.58 3
Peripheral vascular 3.88 3
Ventricular arrhythmia 1.79 1
COPD 5.17 4
Renal failure 1.19 0
Type of PCI
Only drug-eluting stent 57.46 57
Bare-metal stent 41.15 40
No stent 1.39 1
New York State, January 1, 2003, to June 30, 2006. C statistic 0.67.
Abbreviations as in Table 1.f culprit vessel PCI (16), no significant difference (21,22), srending in favor of multivessel PCI (14), and significantly
ower rates for multivessel PCI (15,18–20).
Our study is one of the few multicenter population-
ased studies that have been conducted on this topic and
he only one that examines long-term outcomes and the
se of multivessel PCI after discharge as well as during
he index admission. Predictors of use of multivessel PCI
t the time of primary PCI were younger age, lower and
igher ejection fractions (as opposed to ejection fractions
n the middle range), absence of chronic total occlusion,
ncreased TIMI flow grade 2, and the use of bare-metal
rization Strategy During Index Procedure in STEMI Patients With
ascularization
PCI
% With Multivessel Revascularization
at the Time of PPCI
(n  503)
Standardized
Difference (%)
54.67 1.60
21.67 2.43
14.12 4.47
9.54 4.90
25.05 8.96
50.30 1.99
24.06 0.46
17.10 3.76
8.55 7.41
3.38 5.94
7.55 5.51
16.30 0.00
28.23 0.88
44.53 3.99
4.77 9.28
7.95 6.99
5.37 0.87
43.54 6.86
3.78 2.14
4.17 3.09
1.79 0.00
5.37 1.80
1.60 7.33
57.06 1.61
41.35 0.81
1.59 3.39scula
CI
el Rev
e of P
503)
.47
.68
.71
.15
.27
.30
.25
.71
.74
.39
.16
.30
.63
.52
.98
.16
.57
.16
.38
.58
.79
.97
.80
.85
.95
.19tents.
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27We found that patients with multivessel disease STEMI
ndergoing multivessel primary PCI at the time of the index
rocedure had mortality rates that were trending higher
han rates for patients with culprit vessel PCI alone. Also,
hen outcomes for the subset of patients without hemody-
amic instability, ejection fraction 20%, or malignant
entricular arrhythmia were examined, patients with culprit
essel PCI alone had lower in-hospital mortality rates (0.9%
s. 2.4%, p  0.04). This subset was chosen because it was
he group of patients in our database that came closest to the
efinition of hemodynamic compromise in the ACC/AHA
Table 3. Risk Factor Prevalence After Propensity Match According to Reva
Multivessel CAD: Culprit Vessel Versus Staged In-Hospital Multivessel Rev
Risk Factor
% in Study Population
(n  518)
% With Culprit V
at the
(n
Demographic factors
Age, yrs
59 or less 48.46
60–69 28.96
70–79 16.80
80 or more 5.79
Female 17.37
Cardiac factors
No. of vessels diseased
2 no proximal LAD 41.12
2 with proximal LAD 16.99
3 no proximal LAD 27.22
3 with proximal LAD 14.67
Ejection fraction
19% or less 1.16
20%–29% 6.56
30%–39% 18.92
40%–49% 30.50
50% or more 42.86
Hemodynamic status
Unstable 3.28
CHF history
This admission 3.21
Chronic total occlusion 7.14
TIMI ﬂow grade 2 51.93
Comorbidities
Cerebrovascular 4.25
Peripheral vascular 2.51
Ventricular arrhythmia 0.77
COPD 6.76
Renal failure 0.39
Type of PCI
Only drug-eluting stent 66.22
Bare-metal stent 30.89
No stent 2.90
New York State, January 1, 2003, to June 30, 2006. C statistic 0.69.
Abbreviations as in Table 1.ecommendations. Because the current ACC/AHA guide- tines recommend culprit vessel PCI for patients without
emodynamic compromise, our findings support the recom-
endations (3).
Another part of our study consisted of comparing differ-
nces in mortality between multivessel disease STEMI
atients treated with culprit vessel PCI and those patients
ho did not undergo multivessel PCI during the index
rocedure but did undergo multivessel PCI within 60 days
fter the index procedure, either during the index admission
r afterward. Conclusions from these analyses were that
atients who underwent multivessel PCI within 60 days of
rization Strategy During Index Procedure in STEMI Patients With
arization
Revascularization
of PPCI
9)
% With Staged In-Hospital
Multivessel Revascularization
(n  259)
Standardized
Difference (%)
49.03 2.32
28.96 0.00
16.99 1.03
5.02 6.62
15.83 8.16
42.08 3.92
15.83 6.17
27.80 2.60
14.29 2.18
1.16 0.00
5.79 6.24
19.31 1.97
29.34 5.03
44.40 6.24
3.09 2.17
2.32 9.08
7.72 4.50
53.28 5.41
4.63 3.83
2.32 2.47
1.16 8.83
6.95 1.54
0.39 0.00
66.80 2.45
30.50 1.67
2.70 2.30scula
ascul
essel
Time
 25
47.88
28.96
16.60
6.56
18.92
40.15
18.15
26.64
15.06
1.16
7.34
18.53
31.66
41.31
3.47
4.10
6.56
50.58
3.86
2.70
0.39
6.56
0.39
65.64
31.27
3.09he index procedure fared better than patients who were
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28imited to culprit vessel PCI within 60 days. The multivessel
CI patients had lower mortality rates at all time intervals
hat were examined, and their mortality rate was signifi-
antly lower at 12 months (1.3% vs. 3.3%, p  0.04). A
imitation of this set of analyses is that the multivessel PCI
roup underwent the second procedure sometime within 60
ays after discharge, and the culprit vessel group to which it
as matched was alive at 60 days without multivessel PCI.
owever, this should favor the culprit vessel revasculariza-
ion group, so the findings are conservative with regard to
Table 4. Risk Factor Prevalence After Propensity Match According to Reva
Multivessel CAD: Culprit Vessel Versus Staged Multivessel Revascularizat
Risk Factor
% in Study Population
(n  1,056)
% With Cul
Revascu
(n 
Demographic factors
Age, yrs
59 or less 52.32 53
60–69 25.84 26
70–79 14.31 13
80 or more 7.53 7
Female 22.03 22
Cardiac factors
No. of vessels diseased
2 no proximal LAD 43.77 43
2 with proximal LAD 20.82 21
3 no proximal LAD 24.07 24
3 with proximal LAD 11.34 10
Ejection fraction
19% or less 1.30 1
20%–29% 6.23 6
30%–39% 18.12 18
40%–49% 32.06 31
50% or more 42.29 41
Hemodynamic status
Unstable 2.70 2
CHF history
This admission 3.81 3
Chronic total occlusion 8.55 8
TIMI ﬂow grade 2 53.62 54
Comorbidities
Cerebrovascular 3.53 3
Peripheral vascular 3.81 4
Ventricular arrhythmia 0.84 1
COPD 4.83 4
Renal failure 0.56 0
Type of PCI
Only drug-eluting stent 69.14 71
Bare-metal stent 28.07 26
No stent 2.79 2
New York State, January 1, 2003, to June 30, 2006. C statistic 0.62.
Abbreviations as in Table 1.he advantage of staged revascularization. mWhen the staged PCI patients were limited to patients
ho underwent the second procedure during the index
dmission but not during the index procedure, none of the
ortality differences was statistically significant, although
he staged revascularization group had lower mortality rates
t all time intervals examined.
A caveat regarding the methodology of the study is that
t is an observational study and is therefore subject to
election bias, whereby patients were chosen for 1 of the
reatment options because of characteristics that would
rization Strategy During Index Procedure in STEMI Patients With
ithin 60 Days of Index Procedure
ssel
on
% With Multivessel Revascularization
Within 60 days
(n  538)
Standardized
Difference (%)
51.12 4.84
25.65 0.85
15.61 7.44
7.62 0.70
21.19 4.04
44.05 1.12
20.63 0.92
23.42 3.04
11.90 3.52
1.12 3.28
5.95 2.31
17.84 1.45
32.16 0.40
42.94 2.63
2.97 3.44
4.28 4.86
8.18 2.66
52.60 4.10
3.72 2.01
3.53 2.91
0.56 6.13
5.58 6.94
0.56 0.00
67.29 8.05
30.11 9.11
2.60 2.26scula
ion W
prit Ve
larizati
538)
.53
.02
.01
.43
.86
.49
.00
.72
.78
.49
.51
.40
.97
.64
.42
.35
.92
.65
.35
.09
.12
.09
.56
.00
.02
.97ake that option more preferable and the other option less
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29referable. We tried to control for this bias by propensity
atching patients so that each patient with culprit vessel
CI would be matched with a patient with similar charac-
eristics that had a bearing on outcomes. The fact that the
ercent standardized differences in prevalence of the various
atient characteristics were all 10% supports the assump-
ion that there is good balance between the propensity
atched groups (23). Also, the C statistic, a measure of the
iscrimination of the model, ranged from 0.63 to 0.69.
hese values are reasonably good for propensity models,
here high values are not as desirable because there is a
reater likelihood that there will be difficulty matching
atients on numerous intersecting characteristics.
Nevertheless, residual bias might still exist. This is particu-
arly true when there are many potentially unmeasured con-
ounders that could explain why multivessel PCI is performed
uring the primary PCI. These include persistent pain/ST-
egment elevation after dilation of the culprit vessel or another
esion causing compromised TIMI flow as well as situations in
hich the culprit lesion has been easily fixed. To the extent
Table 5. Mortality Rates (%) for Propensity Matched Multivessel Disease S
Outcome by Subgroup
Culprit Vessel Reva
at the Time o
All patients n  503
Death, %
In-hospital 2.0
12 months 5.5
24 months 6.6
42 months 10.8
Patients without hemodynamic instability, LVEF 20%,
malignant ventricular arrhythmia
n  458
Death, %
In-hospital 0.9
12 months 4.2
24 months 4.9
42 months 6.7
Median follow-up 22.54 months.
LVEF left ventricular ejection fraction; PPCI primary percutaneous coronary intervention; ST
Table 6. Mortality Rates (%) for Propensity Matched
PCI With and Without Staged In-Hospital Multivessel
Outcome by Subgroup
Culprit Vessel
Revascularization
Stage
All patients n  259
Death, %
In-hospital 1.9
12 months 5.5
24 months 7.4
42 months 8.4
Median follow-up 21.91 months.PCI percutaneous coronary intervention; STEMI ST-segment elevationhat these confounders affect outcomes, the results reported
ere might contain biases in either direction.
Another caveat of the study is that we were only able to
apture mortality in New York State with New York’s
ital statistics data. Consequently, if New York patients
oved out of state and died there, the mortality was not
ecorded in our study. If this occurred substantially more
ften in either subgroup, the results would be biased.
owever, we see no reason why there would be a bias in
avor of either type of strategy, and an earlier study
emonstrated that there was not a bias in this regard (9).
Also, like previous studies comparing culprit vessel and
ultivessel PCI for STEMI patients, the statistical power
f our study was limited. For example, assuming an in-
ospital mortality rate of 2% for culprit vessel PCI, a sample
f 500 pairs, and a Type I error of 0.05, the power to detect
5% mortality rate in multivessel PCI as significantly
ifferent is 0.67. In patients without hemodynamic compro-
ise, an in-hospital mortality rate of 1% for culprit vessel
CI is more reasonable, and for 500 pairs of patients and a
Patients by Revascularization Strategy During the Index Procedure
ization Multivessel Revascularization
at the Time of PPCI
Percentage
Difference p Value
n  503
3.4 1.4 0.14
7.1 1.6 0.23
8.6 2.0 0.17
11.8 1.0 0.23
n  458
2.4 1.5 0.04
5.8 1.6 0.13
7.2 2.3 0.07
10.4 3.7 0.08
T-segment elevation myocardial infarction.
vessel Disease STEMI Patients With Culprit Vessel
scularization
ltivessel Revascularization
Index Hospital Stay
Percentage
Difference p Value
n  259
1.2 0.7 0.48
3.9 1.6 0.53
6.3 1.1 0.71
6.3 2.1 0.72TEMI
scular
f PPCIMulti
Reva
d Mu
Duringmyocardial infarction.
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30ype I error of 0.05, the power to detect a significant
ifference in a mortality rate of 3% for multivessel PCI is
.54. This power rises to 0.83 when distinguishing between
amples with mortality rates of 1% and 4%.
In conclusion, the findings of our study support the
CC/AHA recommendations regarding the use of culprit
essel PCI for STEMI patients with multivessel disease at
he time of the index revascularization except when patients
re hemodynamically compromised. However, we also
ound that, when patients undergo staged multivessel revas-
ularization after the index procedure but within 60 days,
ortality rates were significantly lower at 12 months. Also,
or the subset of patients undergoing staged PCI in the
ndex admission, there was no difference in outcomes
etween culprit vessel PCI and staged PCI. Thus, our
ndings indicate that, for STEMI patients with multivessel
isease, staged PCI after the index procedure is associated
ith risk-adjusted mortality rates that are comparable to the
ate for culprit vessel PCI.
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